Clinical trials: CD19-positive
Acute Lymphobkastic Leukemia
To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004
This is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of STR-P004 in…
- Trial name
- NCT07245251
- Testing
- STR-P004
- Volunteers
- 11 people
- Sponsor
- Starna Therapeutics
Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder)
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
- Trial name
- NCT05348889
- Testing
- 1A46 Injection
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chimagen Biosciences, Ltd
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell…
- Conditions
- Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT06037018
- Testing
- CC312
- Where
- China
- Volunteers
- 44 people
- Sponsor
- CytoCares Inc
B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL)
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia.
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07205315
- Testing
- GT801 Injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Grit Biotechnology
Systemic Lupus Erythematosus
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics…
- Trial name
- CARLYSLE (NCT06333483)
- Testing
- Obecabtagene autoleucel (obe-cel)
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Autolus Limited
Non Hodgkin Lymphoma (NHL), Leukaemia
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
- Trial name
- SAPPHIRE (NCT07518329)
- Testing
- ALA-101
- Where
- 5 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Arovella Therapeutics Ltd
CD19-positive, Acute Lymphoblastic Leukemia
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia.
- Trial name
- NCT03798509
- Testing
- Human CD19 targeted T Cells Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Non-hodgkin Lymphoma,B Cell
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in…
- Trial name
- Trident19-H (NCT03497533)
- Testing
- TriCAR-T-CD19
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Timmune Biotech Inc.
Hematological Malignancy (Leukemia- Lymphoma)
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in…
- Trial name
- NCT06948981
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Grit Biotechnology
Non Hodgkin Lymphoma
CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma
To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.
- Trial name
- NCT04237428
- Testing
- CD19 CAR-T cells infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory acute lymphoblastic leukemia.
- Trial name
- NCT04230473
- Testing
- single dose of CNCT19
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Juventas Cell Therapy Ltd.
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04888468
- Testing
- pCAR-19B cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of ssCART-19 in the treatment of patients with CD19 positive relapsed or refractory acute lymphoblastic…
- Trial name
- NCT04825496
- Testing
- ssCART-19 Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
This is a phase I clinical study to evaluate the safety and efficacy of CAR-T infusion preparation in the treatment of CD19-positive relapsed/refractory non-Hodgkin lymphoma.
- Conditions
- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma
- Trial name
- NCT05420493
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
The purpose of this study is to determine whether AFM11 is safe and active in the treatment of relapsed and/or refractory Non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT02106091
- Testing
- AFM11
- Where
- 9 sites in United States, Czechia and 2 more
- Volunteers
- 16 people
- Sponsor
- Affimed GmbH
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute…
- Trial name
- NCT04684147
- Testing
- single dose of CNCT19
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Juventas Cell Therapy Ltd.